Top 10 Prostate Cancer Stories of 2018

Top 10 Prostate Cancer Stories of 2018
Prostate Cancer News Today provided readers with daily coverage of important discoveries, potential blood tests and disease markers, as well as treatment developments related to prostate cancer during 2018. We look forward to reporting more news to patients, family members and caregivers during 2019. Here are the Top 10 most-read stories of 2018, with a brief description of what made them interesting for the prostate cancer community. No. 10 – "Focal Ultrasound Prostate Ablation Shows Promising Results with Fewer Side Effects" A procedure called high-intensity focal ultrasound (HIFU) — partial ablation of the prostate — led to a significant drop in prostate-specific antigen (PSA) levels in a study with 50 prostate cancer patients, It also had fewer side effects than traditional surgery and radiation therapy. HIFU, which removes the diseased tissue only, also led to absence of cancer tissue in the targeted area as assessed via biopsy. However, scores of urinary symptoms and quality of life went back to baseline 3-6 months after HIFU in 78% of patients. Also, 85% of patients maintained erectile function, while 15% had erectile dysfunction at 12 months. No. 9 – "ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows" In January, we published the first of three stories about OncBioMune‘s investigational cancer vaccine ProscaVax. This immunotherapy candidate consists in a combination of the PSA protein with two molecules produced by immune cells called interleukin-2 and GM-CSF. Results of a Phase 1a/1b clinical trial (NCT02058680) showed that intradermal (in the skin) injections of ProscaVax reduced tumor growth in 70% of patients, which lasted for at least 31 weeks. Also at 31 weeks, 15 of 18 patients had increa
Subscribe or to access all post and page content.